This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Indinavir
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption=""/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption=""/> | ||
| - | ===Better Known as:=== | + | ===Better Known as: Crixivan=== |
| - | * Marketed By:<br /> | + | * Marketed By: Merck & Co.<br /> |
* Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | * Major Indication: [[Human Immunodeficiency Virus]] Infection<br /> | ||
* Drug Class: [[HIV Protease]] Inhibitor | * Drug Class: [[HIV Protease]] Inhibitor | ||
| - | * Date of FDA Approval (Patent Expiration): <br /> | + | * Date of FDA Approval (Patent Expiration): 1996 (2014) <br /> |
* 2006 Sales: | * 2006 Sales: | ||
* Importance: | * Importance: | ||
Revision as of 19:20, 1 December 2010
|
Better Known as: Crixivan
- Marketed By: Merck & Co.
- Major Indication: Human Immunodeficiency Virus Infection
- Drug Class: HIV Protease Inhibitor
- Date of FDA Approval (Patent Expiration): 1996 (2014)
- 2006 Sales:
- Importance:
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| HIV Protease Inhibitor Pharmacokinetics | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Tmax (hr) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Cmax (ng/ml) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Bioavailability (%) | Ritonavir | Tipranavir | 65 | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Protein Binding (%) | 99 | Tipranavir | 61 | 98 | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| T1/2 (hr) | 4 | Tipranavir | 1.8 | 7-12 | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| AUC (ng/ml/hr) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| IC50 (nM) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Dosage (mg) | Ritonavir | Tipranavir | Indinavir | Saquinavir | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
| Metabolism | Hepatic (CYP3A4) | Tipranavir | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Amprenavir | Fosamprenavir | Lopinavir | Ritonavir | Darunavir | Atazanavir | Nelfinavir |
References
